GeneCentric Therapeutics, a company specializing in RNA-based diagnostics for precision medicine, has recently published new findings from the Piedmont study. This study utilized real-world data to identify predictive biomarkers for approved first-line treatments in non-small cell lung cancer (NSCLC). The results highlight the clinical benefit of GeneCentric's RNA-based Antifolate Predictive Response Signature (AF-PRS) in guiding treatment selection for lung cancer patients.
The publication of these initial results marks an important milestone in the development of AF-PRS as a clinical diagnostic test. GeneCentric is collaborating with LabCorp to further advance this innovative approach to precision medicine. The retrospective analysis was published in the esteemed peer-reviewed journal Clinical Cancer.